BIAS
PACB icon

Beacon Investment Advisory Services’s Pacific Biosciences PACB Stock Holding History

Beacon Investment Advisory Services’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,315
Closed -$131K – 285
2023
Q1 		$131K Hold
11,315
– – 0.01% 274
2022
Q4 		$92.6K Sell
11,315
-3,292
-23% -$28.4K ﹤0.01% 275
2022
Q3 		$85K Sell
14,607
-997
-6% -$5.72K ﹤0.01% 271
2022
Q2 		$69K Buy
15,604
+270
+2% +$1.64K ﹤0.01% 280
2022
Q1 		$140K Sell
15,334
-479
-3% -$5.51K 0.01% 291
2021
Q4 		$324K Buy
15,813
+132
+0.8% +$3.19K 0.01% 253
2021
Q3 		$401K Buy
15,681
+1,990
+15% +$59K 0.02% 224
2021
Q2 		$479K Buy
13,691
+4,587
+50% +$133K 0.02% 211
2021
Q1 		$303K Buy
+9,104
New +$319K 0.01% 250

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Beacon Investment Advisory Services's PACB Position: Q2 2023 in Review

Beacon Investment Advisory Services sold out of Pacific Biosciences (PACB) in Q2 2023, closing a stake of 11,315 shares — an estimated $131K sold.

Beacon Investment Advisory Services first reported a position in PACB in Q1 2021 and held it in 9 quarters. The position peaked at $479K in Q2 2021. 272 funds tracked by Wall St. Rank hold PACB as of Q2 2023.

  • Beacon Investment Advisory Services reported no remaining Pacific Biosciences position as of Q2 2023 after selling out during the quarter.
  • Beacon Investment Advisory Services sold 11,315 Pacific Biosciences shares in Q2 2023, an estimated $131K.
  • Beacon Investment Advisory Services first reported a position in Pacific Biosciences in Q1 2021 and held it in 9 quarters.
  • Beacon Investment Advisory Services's Pacific Biosciences position peaked at $479K in Q2 2021.
  • 272 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2023.

Based on Beacon Investment Advisory Services's 13F filing for Q2 2023, filed 21 Jul 2023.